Jacobs & Co. CA Decreases Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)


Share on StockTwits

Jacobs & Co. CA lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 34,534 shares of the medical equipment provider’s stock after selling 300 shares during the period. Jacobs & Co. CA’s holdings in Zimmer Biomet were worth $5,528,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Delta Asset Management LLC TN boosted its holdings in Zimmer Biomet by 10.0% during the fourth quarter. Delta Asset Management LLC TN now owns 701 shares of the medical equipment provider’s stock worth $108,000 after buying an additional 64 shares in the last quarter. Synovus Financial Corp lifted its holdings in shares of Zimmer Biomet by 4.0% in the fourth quarter. Synovus Financial Corp now owns 1,686 shares of the medical equipment provider’s stock valued at $259,000 after purchasing an additional 65 shares in the last quarter. Advisor Partners LLC lifted its holdings in shares of Zimmer Biomet by 1.5% in the fourth quarter. Advisor Partners LLC now owns 4,323 shares of the medical equipment provider’s stock valued at $666,000 after purchasing an additional 65 shares in the last quarter. Bridge Creek Capital Management LLC lifted its holdings in shares of Zimmer Biomet by 0.3% in the fourth quarter. Bridge Creek Capital Management LLC now owns 23,544 shares of the medical equipment provider’s stock valued at $3,628,000 after purchasing an additional 75 shares in the last quarter. Finally, Brookstone Capital Management lifted its holdings in shares of Zimmer Biomet by 2.0% in the fourth quarter. Brookstone Capital Management now owns 4,360 shares of the medical equipment provider’s stock valued at $672,000 after purchasing an additional 84 shares in the last quarter. Institutional investors and hedge funds own 87.17% of the company’s stock.

ZBH has been the topic of several recent research reports. SVB Leerink upped their price target on shares of Zimmer Biomet from $185.00 to $190.00 and gave the company an “outperform” rating in a report on Monday, February 8th. Evercore ISI raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $175.00 price objective for the company in a research report on Monday, January 4th. Piper Sandler boosted their price objective on shares of Zimmer Biomet from $185.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday, February 5th. Needham & Company LLC boosted their price objective on shares of Zimmer Biomet from $185.00 to $192.00 and gave the company a “strong-buy” rating in a research report on Friday, February 5th. Finally, TheStreet lowered shares of Zimmer Biomet from a “b-” rating to a “c+” rating in a research report on Monday, March 29th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $165.65.

ZBH traded up $2.16 during trading on Thursday, hitting $164.91. 3,710 shares of the company’s stock were exchanged, compared to its average volume of 1,258,443. The company has a current ratio of 2.18, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.68 and a 1 year high of $170.05. The stock has a 50 day moving average price of $160.20 and a 200 day moving average price of $151.65. The firm has a market cap of $34.35 billion, a P/E ratio of 1,017.25, a price-to-earnings-growth ratio of 4.32 and a beta of 1.34.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 4th. The medical equipment provider reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.05. The company had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.08 billion. Zimmer Biomet had a net margin of 0.52% and a return on equity of 10.07%. Zimmer Biomet’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.30 earnings per share. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 4.8 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, April 30th. Stockholders of record on Monday, March 29th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Friday, March 26th. This represents a $0.96 annualized dividend and a dividend yield of 0.58%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.20%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products.

Featured Story: How Do Front-End Loads Impact an Investment?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.